Fiche centre
CHU de Bordeaux
Pessac — France
Essais liés4clinical trials
VillePessaclocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06806033
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Fludarabine, Busulfan, Thymoglobuline | Cancer | Phase 2 | NCT00841724 | ITT 08-01 — Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | COMPLETED |
| Domvanalimab | Cancer | Phase 2 | NCT06727565 | VELOCITY-HNSCC — Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | ACTIVE_NOT_RECRUITING |
| BIOPARK — Biomarkers in Parkinsonian Syndromes | Parkinson | À vérifier | NCT02114242 | BIOPARK — Biomarkers in Parkinsonian Syndromes | UNKNOWN |
| Obinutuzumab | Cancer | Phase 2 | NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | RECRUITING |